This time of the year can be uncomfortable and testing for some CEO's and Executive Chair's, especially when the bluff and bluster and "its coming" has been thick and fast during the last financial year but many snouts have have had a good feed from the trough in the meantime.
Perhaps this current financial year is going to be the "Year to deliver" for WHA.
I have to admit the financials for FY18 always were going to be less than impressive but they went somewhat further down that path than expected. Even though there is a decent wad of capital sitting there the earnings were a little off the mark and the costs were a little over the mark.
Lets see if the almighty SAMR approval arrives sometimes early enough in this current FY and can support a difference to the earnings through the highly dependent conditional agreement in Shandong.
Some options are floating about at $1.60 but they don't fall due until 2020.
So can't see a compelling driver of the share price at this point, the steam has gone out of it lately.
- Forums
- ASX - By Stock
- WNX
- Ann: Financial Year 2018 - Summary
Ann: Financial Year 2018 - Summary, page-30
-
-
- There are more pages in this discussion • 102 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WNX (ASX) to my watchlist
|
|||||
Last
3.0¢ |
Change
-0.001(3.23%) |
Mkt cap ! $38.69M |
Open | High | Low | Value | Volume |
3.0¢ | 3.0¢ | 3.0¢ | $1.14K | 38K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 347278 | 2.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.0¢ | 726019 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 347278 | 0.029 |
3 | 1152458 | 0.028 |
3 | 82053 | 0.027 |
4 | 733186 | 0.026 |
6 | 2195000 | 0.025 |
Price($) | Vol. | No. |
---|---|---|
0.030 | 726019 | 1 |
0.031 | 257351 | 1 |
0.032 | 1625000 | 3 |
0.033 | 1280000 | 2 |
0.034 | 500000 | 1 |
Last trade - 10.48am 16/07/2024 (20 minute delay) ? |
Featured News
WNX (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online